All documents and minutes (PASC, ESC & MSAC) relating to MSAC 1530
Dear Medical Services Advisory Committee,
On behalf of the Alpha-1 Organisation Australia Inc and the thousands of patients affected by alpha-1 antitrypsin deficiency in Australia I would like copies of all documents associated with MSAC 1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD), in order to better understand the recommendation made and the process used in reaching this recommendation.
Yours faithfully,
Ian Saunders
Treasurer
Alpha-1 Organisation Australia Inc
Good morning Mr Saunders,
I refer to your request received by the Department of Health and Aged Care
(the department) on 22 May 2024 for access to documents under the Freedom
of Information Act 1982 (FOI Act). You have requested access to:
All documents associated with MSAC 1530 - Purified human alpha1-proteinase
inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor
deficiency, leading to chronic obstructive pulmonary disease (COPD).
The department has reviewed the scope of your request and believes that in
its current form there could be an unreasonable diversion of resources to
process your request.
Taking this into consideration, we are contacting you to help you clarify
the scope of your request.
Scope clarification
Narrowing to certain types of documents
Your request is very broad in nature and will include a very large number
of documents. You may wish to consider narrowing the types of documents
you are requesting, such as submission documents etc.
In addition, you may wish to exclude correspondence of a general
administrative nature from your request.
Narrowing timeframes
You may also wish to consider specifying a time-frame for the requested
correspondence, for example 1 Jan 2018 – 31 March 2020.
We would be grateful if you could review the above and provide a response
by close of business 27 May 2024.
Kind regards,
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-----Original Message-----
From: Ian Saunders [1][FOI #11435 email]
Sent: Wednesday, May 22, 2024 4:38 PM
To: FOI [2][email address]
Subject: Freedom of Information request - All documents and minutes (PASC,
ESC & MSAC) relating to MSAC 1530
REMINDER: Think before you click! This email originated from outside our
organisation. Only click links or open attachments if you recognise the
sender and know the content is safe.
Dear Medical Services Advisory Committee,
On behalf of the Alpha-1 Organisation Australia Inc and the thousands of
patients affected by alpha-1 antitrypsin deficiency in Australia I would
like copies of all documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD), in order to better understand the recommendation made and the
process used in reaching this recommendation.
Yours faithfully,
Ian Saunders
Treasurer
Alpha-1 Organisation Australia Inc
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[3][FOI #11435 email]
Is [4][Medical Services Advisory Committee request email] the wrong address for Freedom of Information
requests to Medical Services Advisory Committee? If so, please contact us
using this form:
[5]https://www.righttoknow.org.au/change_re...
This request has been made by an individual using Right to Know. This
message and any reply that you make will be published on the internet.
More information on how Right to Know works can be found at:
[6]https://www.righttoknow.org.au/help/offi...
Please note that in some cases publication of requests and responses will
be delayed.
If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.
-------------------------------------------------------------------
"Important: This transmission is intended only for the use of the
addressee and may contain confidential or legally privileged information.
If you are not the intended recipient, you are notified that any use or
dissemination of this communication is strictly prohibited. If you
receive this transmission in error please notify the author immediately
and delete all copies of this transmission."
References
Visible links
1. mailto:[FOI #11435 email]
2. mailto:[email address]
3. mailto:[FOI #11435 email]
4. mailto:[Medical Services Advisory Committee request email]
5. https://www.righttoknow.org.au/change_re...
6. https://www.righttoknow.org.au/help/offi...
Dear Riley,
Thank you for your response. It is obviously difficult to be specific when we don't know what documents exist, however we would like:
1. Grifols and CSL submissions
2. The Assessment Report
3, The full (unredacted) public report "1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)
4. Economic evaluation documents which supported the assessment
Thank you once again for your assistance in this matter.
Yours sincerely,
Ian Saunders
Dear Riley
I had replied to your message once, but the response seems to have gone missing.
We would like:
1. Submissions by CSL and Grifols
2. The full Assessment Report related to the MSAC submission (around 2017 - 2018)
3. The economic analysis carried out relating to cost/benefit of augmentation therapy
4. The full (non-redacted) public report called “1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase inhibitor deficiency, leading to chronic obstructive pulmonary disease (COPD)” from 2018
Yours sincerely,
Ian Saunders
Good afternoon Mr Saunders,
Acknowledgement of receipt of Freedom of Information request
We refer to your emails of 25 May 2024 and 29 May 2024 clarifying the
scope of your request.
We confirm the scope of your request has been updated as follows:
The following documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD):
1. Grifols and CSL submissions
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018)
3. The economic analysis carried out relating to cost/benefit of
augmentation therapy
4. The full (unredacted) public report "1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD) from 2018
The reference number for your request is FOI-5155. Please ensure that you
quote this number in future correspondence with us concerning this
request.
Timeframes
Your request was received on 22 May 2024. The statutory timeframe for
processing your request is 30 calendar days and you should expect to be
notified of a decision from the department on or before 21 June 2024. The
period of 30 days may be extended if the department needs to consult
third parties or for other reasons. We will advise you if this happens.
Other information
The department may impose a charge for the work involved in providing
access to the documents. If this request attracts a charge you will be
notified in writing.
Unless you advise otherwise:
· any draft and duplicate documents will be excluded from the
scope of your request, and
· any public service employee names below Senior Executive Service
level and direct telephone numbers of all staff will be excluded from the
scope of your request under s22(1)(a)(ii) of the FOI Act.
Please note that information released under the FOI Act may later be
published online on our disclosure log
[1]www.health.gov.au/resources/foi-disclosure-log, subject to certain
exceptions. (For example, personal information will not be published where
this would be unreasonable.)
You can contact the FOI team via email at [2][email address] or by phone
on 02 6289 1666, should you have any questions.
Kind regards,
Hannah
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal and Assurance Division
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [3][email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-----Original Message-----
From: Ian Saunders <[FOI #11435 email]>
Sent: Wednesday, May 29, 2024 2:12 PM
To: FOI <[email address]>
Subject: Re: FOI 5155 - Scope clarification [SEC=OFFICIAL]
REMINDER: Think before you click! This email originated from outside our
organisation. Only click links or open attachments if you recognise the
sender and know the content is safe.
Dear Riley
I had replied to your message once, but the response seems to have gone
missing.
We would like:
1. Submissions by CSL and Grifols
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018) 3. The economic analysis carried out relating to cost/benefit of
augmentation therapy 4. The full (non-redacted) public report called
“1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the
treatment of alpha1-proteinase inhibitor deficiency, leading to chronic
obstructive pulmonary disease (COPD)” from 2018 Yours sincerely, Ian
Saunders
-----Original Message-----
Good morning Mr Saunders,
I refer to your request received by the Department of Health and Aged
Care (the department) on 22 May 2024 for access to documents under the
Freedom of Information Act 1982 (FOI Act). You have requested access to:
All documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of
alpha1-proteinase inhibitor deficiency, leading to chronic obstructive
pulmonary disease (COPD).
The department has reviewed the scope of your request and believes that
in its current form there could be an unreasonable diversion of resources
to process your request.
Taking this into consideration, we are contacting you to help you clarify
the scope of your request.
Scope clarification
Narrowing to certain types of documents
Your request is very broad in nature and will include a very large number
of documents. You may wish to consider narrowing the types of documents
you are requesting, such as submission documents etc.
In addition, you may wish to exclude correspondence of a general
administrative nature from your request.
Narrowing timeframes
You may also wish to consider specifying a time-frame for the requested
correspondence, for example 1 Jan 2018 – 31 March 2020.
We would be grateful if you could review the above and provide a response
by close of business 27 May 2024.
Kind regards,
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[4][FOI #11435 email]
This request has been made by an individual using Right to Know. This
message and any reply that you make will be published on the internet.
More information on how Right to Know works can be found at:
[5]https://www.righttoknow.org.au/help/offi...
Please note that in some cases publication of requests and responses will
be delayed.
If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.
-------------------------------------------------------------------
"Important: This transmission is intended only for the use of the
addressee and may contain confidential or legally privileged information.
If you are not the intended recipient, you are notified that any use or
dissemination of this communication is strictly prohibited. If you
receive this transmission in error please notify the author immediately
and delete all copies of this transmission."
References
Visible links
1. http://www.health.gov.au/resources/foi-d...
2. mailto:[email address]
3. mailto:[email address]
4. mailto:[FOI #11435 email]
5. https://www.righttoknow.org.au/help/offi...
Good morning Mr Saunders,
I refer to your request of 22 May 2024 to the Department of Health and
Aged Care (department), seeking access under the Freedom of Information
Act 1982 (Cth) (FOI Act) to the following documents:
The following documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD):
1. Grifols and CSL submissions
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018)
3. The economic analysis carried out relating to cost/benefit of
augmentation therapy
4. The full (unredacted) public report "1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD) from 2018
Notice of Third Party Consultation
Documents have been identified in the scope of your request which contain
information relating to third parties. It has been determined that it
would be appropriate to consult with the affected third parties under
section 27 of the FOI Act prior to a decision on access to those documents
being made.
Section 15(6) of the FOI Act allows the timeframe for processing your
request to be extended by 30 days to facilitate this consultation.
Accordingly, the statutory due date for your request is now 21 July 2024.
The department will continue processing your request and provide you with
a decision on access as soon we are able to do so.
Relevant provisions
The FOI Act, including the provisions referred to in this email, can be
accessed from the Federal Register of Legislation website:
[1]www.legislation.gov.au/Series/C2004A02562.
If you require clarification of any of the matters discussed in this email
you should contact the department’s FOI Section by email at
[2][email address].
Kind regards,
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
From: FOI <[email address]>
Sent: Thursday, May 30, 2024 12:03 PM
To: 'Ian Saunders' <[FOI #11435 email]>
Subject: TRIM: Freedom of Information Request 5155 – Acknowledgement of
Receipt [SEC=OFFICIAL]
Good afternoon Mr Saunders,
Acknowledgement of receipt of Freedom of Information request
We refer to your emails of 25 May 2024 and 29 May 2024 clarifying the
scope of your request.
We confirm the scope of your request has been updated as follows:
The following documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD):
1. Grifols and CSL submissions
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018)
3. The economic analysis carried out relating to cost/benefit of
augmentation therapy
4. The full (unredacted) public report "1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD) from 2018
The reference number for your request is FOI-5155. Please ensure that you
quote this number in future correspondence with us concerning this
request.
Timeframes
Your request was received on 22 May 2024. The statutory timeframe for
processing your request is 30 calendar days and you should expect to be
notified of a decision from the department on or before 21 June 2024. The
period of 30 days may be extended if the department needs to consult
third parties or for other reasons. We will advise you if this happens.
Other information
The department may impose a charge for the work involved in providing
access to the documents. If this request attracts a charge you will be
notified in writing.
Unless you advise otherwise:
· any draft and duplicate documents will be excluded from the
scope of your request, and
· any public service employee names below Senior Executive Service
level and direct telephone numbers of all staff will be excluded from the
scope of your request under s22(1)(a)(ii) of the FOI Act.
Please note that information released under the FOI Act may later be
published online on our disclosure log
[3]www.health.gov.au/resources/foi-disclosure-log, subject to certain
exceptions. (For example, personal information will not be published where
this would be unreasonable.)
You can contact the FOI team via email at [4][email address] or by phone
on 02 6289 1666, should you have any questions.
Kind regards,
Hannah
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal and Assurance Division
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [5][email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-----Original Message-----
From: Ian Saunders <[6][FOI #11435 email]>
Sent: Wednesday, May 29, 2024 2:12 PM
To: FOI <[7][email address]>
Subject: Re: FOI 5155 - Scope clarification [SEC=OFFICIAL]
REMINDER: Think before you click! This email originated from outside our
organisation. Only click links or open attachments if you recognise the
sender and know the content is safe.
Dear Riley
I had replied to your message once, but the response seems to have gone
missing.
We would like:
1. Submissions by CSL and Grifols
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018) 3. The economic analysis carried out relating to cost/benefit of
augmentation therapy 4. The full (non-redacted) public report called
“1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the
treatment of alpha1-proteinase inhibitor deficiency, leading to chronic
obstructive pulmonary disease (COPD)” from 2018 Yours sincerely, Ian
Saunders
-----Original Message-----
Good morning Mr Saunders,
I refer to your request received by the Department of Health and Aged
Care (the department) on 22 May 2024 for access to documents under the
Freedom of Information Act 1982 (FOI Act). You have requested access to:
All documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of
alpha1-proteinase inhibitor deficiency, leading to chronic obstructive
pulmonary disease (COPD).
The department has reviewed the scope of your request and believes that
in its current form there could be an unreasonable diversion of resources
to process your request.
Taking this into consideration, we are contacting you to help you clarify
the scope of your request.
Scope clarification
Narrowing to certain types of documents
Your request is very broad in nature and will include a very large number
of documents. You may wish to consider narrowing the types of documents
you are requesting, such as submission documents etc.
In addition, you may wish to exclude correspondence of a general
administrative nature from your request.
Narrowing timeframes
You may also wish to consider specifying a time-frame for the requested
correspondence, for example 1 Jan 2018 – 31 March 2020.
We would be grateful if you could review the above and provide a response
by close of business 27 May 2024.
Kind regards,
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[8][FOI #11435 email]
This request has been made by an individual using Right to Know. This
message and any reply that you make will be published on the internet.
More information on how Right to Know works can be found at:
[9]https://www.righttoknow.org.au/help/offi...
Please note that in some cases publication of requests and responses will
be delayed.
If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.
-------------------------------------------------------------------
"Important: This transmission is intended only for the use of the
addressee and may contain confidential or legally privileged information.
If you are not the intended recipient, you are notified that any use or
dissemination of this communication is strictly prohibited. If you
receive this transmission in error please notify the author immediately
and delete all copies of this transmission."
References
Visible links
1. http://www.legislation.gov.au/Series/C20...
2. mailto:[email address]
3. http://www.health.gov.au/resources/foi-d...
4. mailto:[email address]
5. mailto:[email address]
6. mailto:[FOI #11435 email]
7. mailto:[email address]
8. mailto:[FOI #11435 email]
9. https://www.righttoknow.org.au/help/offi...
Good morning Mr Saunders,
I refer to your request to the Department of Health and Aged Care (the
department) of 22 May 2024 seeking access to the following under the
Freedom of Information Act 1982 (Cth) (FOI Act):
The following documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD):
1. Grifols and CSL submissions
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018)
3. The economic analysis carried out relating to cost/benefit of
augmentation therapy
4. The full (unredacted) public report "1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD) from 2018
The statutory due date for your request is currently 21 July 2024.
Request for extension of time
Section 15AA of the FOI Act permits the department to extend the statutory
processing timeframe, with your agreement, for a period of up to 30
calendar days.
To ensure that department has undertaken all reasonable steps to identify
all documents relevant to your request, and for the decision maker to make
a well-balanced decision on access to any such documents identified, the
department is seeking your agreement to an extension of 21 calendar days.
If you agree to this extension, the statutory due date will then be 11
August 2024. The department will, however, continue to process your
request as quickly as possible.
It would assist if you could please advise by close of business 19 July
2024 if you agree to this extension of time. If we do not hear from you by
this date or if you do not agree to the extension, the department may
consider seeking an extension of time from the Office of the Australian
Information Commissioner (OAIC) under section 15AB of the FOI Act.
We thank you for your ongoing patience and cooperation as we continue to
process your request.
If you have any questions regarding any of the matters discussed in this
email, please do not hesitate to contact the FOI Section at
[1][email address].
Kind regards
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [2][email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
From: FOI <[email address]>
Sent: Thursday, June 13, 2024 9:41 AM
To: 'Ian Saunders' <[FOI #11435 email]>
Subject: TRIM: Freedom of Information Request 5155 - Notification of
Affected Third Party Consultation [SEC=OFFICIAL]
Good morning Mr Saunders,
I refer to your request of 22 May 2024 to the Department of Health and
Aged Care (department), seeking access under the Freedom of Information
Act 1982 (Cth) (FOI Act) to the following documents:
The following documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD):
1. Grifols and CSL submissions
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018)
3. The economic analysis carried out relating to cost/benefit of
augmentation therapy
4. The full (unredacted) public report "1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD) from 2018
Notice of Third Party Consultation
Documents have been identified in the scope of your request which contain
information relating to third parties. It has been determined that it
would be appropriate to consult with the affected third parties under
section 27 of the FOI Act prior to a decision on access to those documents
being made.
Section 15(6) of the FOI Act allows the timeframe for processing your
request to be extended by 30 days to facilitate this consultation.
Accordingly, the statutory due date for your request is now 21 July 2024.
The department will continue processing your request and provide you with
a decision on access as soon we are able to do so.
Relevant provisions
The FOI Act, including the provisions referred to in this email, can be
accessed from the Federal Register of Legislation website:
[3]www.legislation.gov.au/Series/C2004A02562.
If you require clarification of any of the matters discussed in this email
you should contact the department’s FOI Section by email at
[4][email address].
Kind regards,
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [5][email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
From: FOI <[6][email address]>
Sent: Thursday, May 30, 2024 12:03 PM
To: 'Ian Saunders' <[7][FOI #11435 email]>
Subject: TRIM: Freedom of Information Request 5155 – Acknowledgement of
Receipt [SEC=OFFICIAL]
Good afternoon Mr Saunders,
Acknowledgement of receipt of Freedom of Information request
We refer to your emails of 25 May 2024 and 29 May 2024 clarifying the
scope of your request.
We confirm the scope of your request has been updated as follows:
The following documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD):
1. Grifols and CSL submissions
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018)
3. The economic analysis carried out relating to cost/benefit of
augmentation therapy
4. The full (unredacted) public report "1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of alpha1-proteinase
inhibitor deficiency, leading to chronic obstructive pulmonary disease
(COPD) from 2018
The reference number for your request is FOI-5155. Please ensure that you
quote this number in future correspondence with us concerning this
request.
Timeframes
Your request was received on 22 May 2024. The statutory timeframe for
processing your request is 30 calendar days and you should expect to be
notified of a decision from the department on or before 21 June 2024. The
period of 30 days may be extended if the department needs to consult
third parties or for other reasons. We will advise you if this happens.
Other information
The department may impose a charge for the work involved in providing
access to the documents. If this request attracts a charge you will be
notified in writing.
Unless you advise otherwise:
· any draft and duplicate documents will be excluded from the
scope of your request, and
· any public service employee names below Senior Executive Service
level and direct telephone numbers of all staff will be excluded from the
scope of your request under s22(1)(a)(ii) of the FOI Act.
Please note that information released under the FOI Act may later be
published online on our disclosure log
[8]www.health.gov.au/resources/foi-disclosure-log, subject to certain
exceptions. (For example, personal information will not be published where
this would be unreasonable.)
You can contact the FOI team via email at [9][email address] or by phone
on 02 6289 1666, should you have any questions.
Kind regards,
Hannah
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal and Assurance Division
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [10][email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-----Original Message-----
From: Ian Saunders <[11][FOI #11435 email]>
Sent: Wednesday, May 29, 2024 2:12 PM
To: FOI <[12][email address]>
Subject: Re: FOI 5155 - Scope clarification [SEC=OFFICIAL]
REMINDER: Think before you click! This email originated from outside our
organisation. Only click links or open attachments if you recognise the
sender and know the content is safe.
Dear Riley
I had replied to your message once, but the response seems to have gone
missing.
We would like:
1. Submissions by CSL and Grifols
2. The full Assessment Report related to the MSAC submission (around 2017
- 2018) 3. The economic analysis carried out relating to cost/benefit of
augmentation therapy 4. The full (non-redacted) public report called
“1530 - Purified human alpha1-proteinase inhibitor (A1-PI) for the
treatment of alpha1-proteinase inhibitor deficiency, leading to chronic
obstructive pulmonary disease (COPD)” from 2018 Yours sincerely, Ian
Saunders
-----Original Message-----
Good morning Mr Saunders,
I refer to your request received by the Department of Health and Aged
Care (the department) on 22 May 2024 for access to documents under the
Freedom of Information Act 1982 (FOI Act). You have requested access to:
All documents associated with MSAC 1530 - Purified human
alpha1-proteinase inhibitor (A1-PI) for the treatment of
alpha1-proteinase inhibitor deficiency, leading to chronic obstructive
pulmonary disease (COPD).
The department has reviewed the scope of your request and believes that
in its current form there could be an unreasonable diversion of resources
to process your request.
Taking this into consideration, we are contacting you to help you clarify
the scope of your request.
Scope clarification
Narrowing to certain types of documents
Your request is very broad in nature and will include a very large number
of documents. You may wish to consider narrowing the types of documents
you are requesting, such as submission documents etc.
In addition, you may wish to exclude correspondence of a general
administrative nature from your request.
Narrowing timeframes
You may also wish to consider specifying a time-frame for the requested
correspondence, for example 1 Jan 2018 – 31 March 2020.
We would be grateful if you could review the above and provide a response
by close of business 27 May 2024.
Kind regards,
Riley
FOI Case Officer – Freedom of Information Section
Legal Advice and Legislation Branch
Legal Division | Corporate Operations Group
Australian Government Department of Health and Aged Care
T: 02 6289 1666 | E: [email address]
PO Box 9848, Canberra ACT 2601, Australia
The Department of Health and Aged Care acknowledges First Nations peoples
as the Traditional Owners of Country throughout Australia, and their
continuing connection to land, sea and community. We pay our respects to
them and their cultures, and to all Elders both past and present.
-------------------------------------------------------------------
Please use this email address for all replies to this request:
[13][FOI #11435 email]
This request has been made by an individual using Right to Know. This
message and any reply that you make will be published on the internet.
More information on how Right to Know works can be found at:
[14]https://www.righttoknow.org.au/help/offi...
Please note that in some cases publication of requests and responses will
be delayed.
If you find this service useful as an FOI officer, please ask your web
manager to link to us from your organisation's FOI page.
-------------------------------------------------------------------
"Important: This transmission is intended only for the use of the
addressee and may contain confidential or legally privileged information.
If you are not the intended recipient, you are notified that any use or
dissemination of this communication is strictly prohibited. If you
receive this transmission in error please notify the author immediately
and delete all copies of this transmission."
References
Visible links
1. mailto:[email address]
2. mailto:[email address]
3. http://www.legislation.gov.au/Series/C20...
4. mailto:[email address]
5. mailto:[email address]
6. mailto:[email address]
7. mailto:[FOI #11435 email]
8. http://www.health.gov.au/resources/foi-d...
9. mailto:[email address]
10. mailto:[email address]
11. mailto:[FOI #11435 email]
12. mailto:[email address]
13. mailto:[FOI #11435 email]
14. https://www.righttoknow.org.au/help/offi...